Webinar SummaryPatient recruitment continues to be the number one reason for study delays. It is estimated for every day a drug is not on the market, $1 million USD is lost in revenue, and more importantly, patients suffering from illnesses are left waiting for products that can help them achieve their health goals or provide a better quality of life.
September 18, 2019
Join Veristat and panel of experts at the upcoming MassBio Forum:
August 29, 2019
Veristat is excited to be heading to the Evolution Summit Fall 2019 taking place on Sept 11-13, 2019 in San Diego, CA. We will be co-hosting a Master Class session on Successful Sponsor/CRO Partnerships.
August 2, 2019
As of December 2016, the International Council for Harmonisation (ICH) adopted the revised E6 guideline, entitled “Integrated Addendum to Good Clinical Practice (GCP).” The new regulations within E6(R2) require the Sponsor to manage their study using a risk-based approach.
April 16, 2019
Visit the Veristat booth #19 at the Clinical Operations in Oncology West conference taking place on April 30 and May 1 in Burlingame, CA
24-26 February 2019, The Ritz-Carlton Rancho Mirage, CA
Veristat is excited to join the leading drug development executives and solution providers for a focused discussion of key new drivers shaping drug development at the Evolution Summit Spring 2019 event. At the event, Shaheen Limbada - Executive Vice President of Global Clinical Operations at Veristat – will be available to discuss the latest trends and successes in running patient-centric, cost-effective and more efficient clinical trials.
November 26, 2018
Veristat will attend the upcoming ASH Annual Meeting 2018 taking place in San Diego, California from Dec 1-4, 2018, the premier event in malignant and non-malignant hematology.
August 29, 2018
Meet Veristat at booth # 24 at OCT SoCal 2018! As a full service CRO providing impactful strategies and solutions, Veristat can meet all of your outsourcing needs to support your next clinical trial, program or regulatory submission project.